Open-Label Extension of Other SZ1839 (Iressa) Trials

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Cancer

Treatments: Drug: Gefitinib (Iressa)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00635973

D7913C00026

1839IL/0026

Details and patient eligibility

About

A trial to assess patients who have been treated with Iressa in a previous clinical trial and may benefit from continued treatment with Iressa.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Received treatment in a previous Iressa clinical trial
• Provided Informed Consent to participate in the trial
• 30 days or less since completing the previous Iressa trial.

Exclusion criteria

• Radiotherapy completed more than 14 days before starting treatment in this trial
• Incomplete healing from prior surgery
• Withdrawal from previous Iressa trial due to unacceptable toxicity to major organs

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)